OverviewSuggest Edit

Instil Bio (formerly Immetacyte, Cellular Therapeutics) is an immuno-oncology company that specializes in cell therapies. Its technology platform is based on the use of tumor-infiltrating lymphocytes (TILs), T-cells isolated from the patient’s tumor that can recognize and destroy cancer. The company leverages TIL technology to treat metastatic melanoma patients.

TypePublic
Founded2008
HQDallas, TX, US
Websiteinstilbio.com

Latest Updates

Employees (est.) (Dec 2020)150
Job Openings49
Revenue (FY, 2020)$138 K
Share Price (Sept 2021)$20.3(-12%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Instil Bio

Bronson Crouch

Bronson Crouch

Chief Executive Officer & Chairman
Vijay Chiruvolu

Vijay Chiruvolu

Chief Technical Officer
Zachary Roberts

Zachary Roberts

Chief Medical Officer
George Matcham

George Matcham

Director
Sandeep Laumas

Sandeep Laumas

Chief Financial Officer
Jack B. Nielsen

Jack B. Nielsen

Director
Show more

Instil Bio Office Locations

Instil Bio has an office in Dallas
Dallas, TX, US (HQ)
3963 Maple Ave #350
Dallas, TX, US
5949 Sherry Ln #820
Show all (2)

Instil Bio Financials and Metrics

Instil Bio Revenue

Instil Bio's revenue was reported to be $138 k in FY, 2020
USD

Net income (Q1, 2021)

(23.1m)

EBIT (Q1, 2021)

(23.4m)

Market capitalization (29-Sept-2021)

2.6b

Closing stock price (29-Sept-2021)

20.3

Cash (31-Mar-2021)

609.6m
Instil Bio's current market capitalization is $2.6 b.
Annual
USDFY, 2019FY, 2020

Revenue

138.0k

General and administrative expense

2.6m14.4m

R&D expense

4.0m19.4m

Operating expense total

6.6m33.8m
Quarterly
USDQ1, 2021

General and administrative expense

9.0m

R&D expense

14.4m

Operating expense total

23.4m
Annual
USDFY, 2019FY, 2020

Cash

8.9m241.7m

Prepaid Expenses

391.0k4.4m

Current Assets

9.3m246.1m

PP&E

190.0k55.3m
Quarterly
USDQ1, 2021

Cash

609.6m

Prepaid Expenses

4.1m

Current Assets

613.8m

PP&E

62.9m
Annual
USDFY, 2019FY, 2020

Net Income

(6.5m)(37.7m)

Depreciation and Amortization

20.0k256.0k

Accounts Payable

309.0k(1.1m)

Cash From Operating Activities

(5.3m)(29.6m)
Quarterly
USDQ1, 2021

Net Income

(23.1m)

Depreciation and Amortization

439.0k

Accounts Payable

(271.0k)

Cash From Operating Activities

(17.7m)
USDFY, 2019

Financial Leverage

-1.4 x
Show all financial metrics

Instil Bio Operating Metrics

Mar, 2021

Office and Laboratory Space, square feet

131.28 k

Product Candidates

2
Show all operating metrics

Instil Bio Acquisitions / Subsidiaries

Company NameDateDeal Size
Immetacyte Ltd.March 31, 2020$800 k
Complex Therapeutics, LLC
Instil Bio U.K.

Instil Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Instil Bio Online and Social Media Presence

Embed Graph

Instil Bio News and Updates

Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress

DALLAS, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, announced today that a subset analysis of treatment out…

Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma

Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma

Instil Bio to Present at the Jefferies Virtual Healthcare Conference

DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will present a company o…

Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma

DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma stages IIB to IV with its ITIL-168 TIL therapy.

Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer, today announced the closing of its previously announce…
Show more

Instil Bio Frequently Asked Questions

  • When was Instil Bio founded?

    Instil Bio was founded in 2008.

  • Who are Instil Bio key executives?

    Instil Bio's key executives are Bronson Crouch, Vijay Chiruvolu and Zachary Roberts.

  • How many employees does Instil Bio have?

    Instil Bio has 150 employees.

  • What is Instil Bio revenue?

    Latest Instil Bio annual revenue is $138 k.

  • What is Instil Bio revenue per employee?

    Latest Instil Bio revenue per employee is $920.

  • Who are Instil Bio competitors?

    Competitors of Instil Bio include Achilles Therapeutics, Serotiny and Expression Therapeutics.

  • Where is Instil Bio headquarters?

    Instil Bio headquarters is located at 3963 Maple Ave #350, Dallas.

  • Where are Instil Bio offices?

    Instil Bio has an office in Dallas.

  • How many offices does Instil Bio have?

    Instil Bio has 2 offices.